Opendata, web and dolomites

GAF SIGNED

The First non-cancerogenic Glyoxal Acid-Free fixative for a Formalin-free hospital

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GAF project word cloud

Explore the words cloud of the GAF project. It provides you a very rough idea of what is the project "GAF" about.

cros    cancerogenic    feasibility    therapy    forensic    clients    outsourcing    innovative    huge    plan    finance    second    pathology    gaf    specimens    addressable    toxicity    molecular    off    optimal    hospitals    solution    torino    combined    represented    quality    founders    tissue    august    free    market    2017    healthcare    guarantee    institutes    company    acid    accepted    addax    introducing    services    preserve    absence    formaldehyde    community    serve    validate    fixation    fixative    time    faster    initially    prohibited    veterinary    patient    carcinogenic    biosciences    retain    scientific    university    pathological    primarily    phases    alternative    model    proof    reagent    emergency    substance    union    clinics    business    born    replace    pharmaceutical    tissues    entities    producers    segment    capacity    proposes    first    valid    academic    agreements    spin    structural    scenario    performing    correct    glyoxal    updated    diagnosis    formalin    diagnostic    laboratories    labs    investments    commercialization    medical    private    chemical    preserving    public    customers   

Project "GAF" data sheet

The following table provides information about the project.

Coordinator
ADDAX BIOSCIENCES SRL 

Organization address
address: STRADA MONTGRENO 247
city: TORINO
postcode: 10123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADDAX BIOSCIENCES SRL IT (TORINO) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

ADDAX Biosciences is an academic spin-off of the University of Torino, born after long time research activity of its founders on the pathological tissues. Our company goal is to replace the use of Formalin (a cancerogenic solution of formaldehyde) as fixative, while preserving optimal tissue fixation to guarantee correct diagnosis and therapy. In the European Union, Formaldehyde is recognized as a carcinogenic substance, and its use, production and commercialization is prohibited from August 2017. However, at present there is no valid alternative to Formalin accepted by the scientific community to preserve patient specimens. Our project proposes a huge step forward in the fixative market by introducing an innovative reagent, based on acid-free Glyoxal (GAF), that will allow the optimal tissue fixation at structural and molecular level, combined with the absence of toxicity and carcinogenic activity. The addressable market of our GAF product is primarily represented by the healthcare segment, thus the targeted users and clients are public and private entities performing pathology services, such as: Hospitals, Clinics, Emergency Medical Services, Diagnostic Laboratories, Academic Institutes, Forensic Laboratories, CROs, Veterinary Clinics, Labs and Hospitals. Our business model is initially based in two distinct phases: the first one aimed to achieve a controlled production capacity to serve the first customers and finance the further investments; in the second phase, from second year, we expect a faster scale-up through outsourcing production agreements with major European producers of chemical and pharmaceutical products. In this scenario, Addax will retain the R&D, quality, scientific and market development. The objectives of our Feasibility Study are to validate at European level our proof-of-concept and design an updated Business Plan and Commercialization Plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

SiC-MOSFET (2019)

Gas Sensors for future Ultra Low NOx Emission Legislation – Euro 7

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More